GIUL, LLC v. SHENGHUO MEDICAL, LLC, & Others.

Massachusetts Appeals Court·Decided June 22, 2026·No. 25-P-0435·Unpublished

Opinion

NOTICE: Summary decisions issued by the Appeals Court pursuant to M.A.C. Rule 23.0, as appearing in 97 Mass. App. Ct. 1017 (2020) (formerly known as rule 1:28, as amended by 73 Mass. App. Ct. 1001 [2009]), are primarily directed to the parties and, therefore, may not fully address the facts of the case or the panel's decisional rationale. Moreover, such decisions are not circulated to the entire court and, therefore, represent only the views of the panel that decided the case. A summary decision pursuant to rule 23.0 or rule 1:28 issued after February 25, 2008, may be cited for its persuasive value but, because of the limitations noted above, not as binding precedent. See Chace v. Curran, 71 Mass. App. Ct. 258, 260 n.4 (2008).

COMMONWEALTH OF MASSACHUSETTS

APPEALS COURT

25-P-435

GIUL, LLC

vs.

SHENGHUO MEDICAL, LLC, & others.1

MEMORANDUM AND ORDER PURSUANT TO RULE 23.0

GIUL, LLC (GIUL), invested $64,000 in Shenghuo Medical, LLC

(Shenghuo),2 with the understanding that Shenghuo would use the

funds to secure its own investment in Guided Therapeutics, Inc.

(GTI), the manufacturer and worldwide distributor of a medical

device known as LuViva (LuViva device).3 When the investment did

not produce the return that GIUL and its owner, Paul Conte, anticipated, GIUL sued Shenghuo and its managing members, Michael J. Antonoplos, Richard P. Blumberg, and Mark L. Faupel. GIUL also sued Shenghuo's legal counsel, Mark S. Pearlstein. The majority of GIUL's claims, which were advanced in initial and amended complaints, were dismissed or resolved in favor of the defendants prior to the commencement of a bench trial on claims arising from the Massachusetts Uniform Securities Act, G. L. c. 110A, § 410 (a) (MUSA), and the Massachusetts Consumer Protection Act, G. L. c. 93A, § 11 (c. 93A).4 The judge ruled in favor of the defendants on all remaining claims after the bench trial.

On appeal, GIUL argues, among other things, that the judge applied an incorrect legal standard when he concluded that GIUL failed to prove that the defendants did not disclose material information about GTI's financial condition before GIUL made its investment. We agree. We vacate the portion of the judgment on the MUSA and c. 93A claims as to Shenghuo, Antonoplos, and

Blumberg, and remand for further proceedings consistent with this memorandum and order. We otherwise affirm the judgment.

Background. We summarize the facts found by the judge as articulated in his detailed findings. Faupel coinvented the LuViva device, which, as noted, is manufactured by GTI. Faupel served as chief executive officer of GTI from approximately 2008 through 2013, and again in 2023.5 Blumberg met Faupel around 2006 or 2007 and subsequently became a shareholder in GTI, through which he gained familiarity with the LuViva device, its intended use, and its international commercial prospects. Blumberg reached out to entities that had experience in products being marketed and used internationally. Ultimately, he approached Antonoplos, who had served as chief executive officer of a breast cancer diagnostics company.

Antonoplos was interested in the venture and, in February 2015, Antonoplos and Blumberg formed Shenghuo for the purpose of obtaining licensing rights from GTI, raising capital from investors, and distributing the LuViva device throughout Asia. In the beginning, Antonoplos and Blumberg were the sole managing members of Shenghuo and exercised full control over its

operations. Soon thereafter, Faupel and Pearlstein became members of Shenghuo as well.

In June 2016, Shenghuo entered into a licensing agreement with GTI in which GTI gave Shenghuo a $200,000 conditional loan. Under the agreement, GTI was obligated to repay the loan only if it obtained at least $1 million in additional financing within a specified timeframe. If GTI failed to obtain such financing, it would not incur a repayment obligation, but the agreement allowed for the possibility that any investment from Shenghuo could be converted into GTI common stock.

Within weeks of signing the licensing agreement with GTI, Shenghuo raised approximately $136,000 and sought additional capital to meet the $200,000 investment requirement. Other investors included John Imhoff and Stephen Maloof.6 Both of them had ownership interests in GTI and made investments under subscription agreements drafted by Pearlstein.7 Blumberg communicated with these investors directly and explained that repayment depended on GTI's success in raising funds.

At about the same time, Antonoplos reached out to Conte, who owns and controls GIUL.8 Antonoplos called Conte in June 2016 to solicit investments. The judge found that during this conversation Antonoplos made clear to Conte that Shenghuo had no present income and that its only "real asset was its licens[ing] agreement with GTI." Antonoplos informed Conte that he had already helped raise approximately $136,000 and said that Shenghuo needed an additional $64,000 to complete its funding obligations. Antonoplos further explained in "general terms that anyone willing to invest the remaining $64,000 would receive an ownership interest in Shenghuo as well as a conditional right to repayment of the investment amount." The judge found that Antonoplos told Conte that repayment of the investment "was contingent on GTI raising an additional $1 million and then repaying Shenghuo," and that Antonoplos "never told Conte that repayment would be guaranteed or that there would be any deadline by which Shenghuo would be required to repay this investment." During this same conversation, Conte asked Antonoplos to send him an e-mail message summarizing the investment opportunity.

As requested, on June 9, 2016, Antonoplos followed up in an e-mail message to Conte. The e-mail message stated, "[H]ere is a deal that perhaps you can assist on, but it has a short fuse . . . check the website for [GTI]. . . . [I]f you look at the [GTI] web site you will readily [] see the 'integrity' of this device." Antonoplos then outlined the terms of the investment as follows:

"As part of the aforementioned agreement Shenghuo need to come up with a total of $200K payment (loan) to [GTI] by July 31, 2016 . . . in this regard we have raised $136K so we need an additional $64K by the end of July . . . "For the $64K the following will be offered: "20% interest if loan is paid back within 90 days, another 25% if not paid thereafter and any unpaid balance not paid by December 31, 2016 will accrue and 20% annual compound interest factor[.] "Additionally, the lender will be given 100% warrant coverage on their loan and in addition they will have the ability to convert their loan into stock plus receive an interest in Shenghuo."

Antonoplos then wrote, "Obvious[ly] . . . if there is interest there is more documented info you would need but let me say this[,] I am invested in this[,] it is a winner and the lender is so covered[.] [L]et's discuss further." In the subject line of the e-mail message, Antonoplos provided a link to GTI's website.

Free access — add to your briefcase to read the full text and ask questions with AI

GIUL, LLC v. SHENGHUO MEDICAL, LLC, & Others., (Mass. Ct. App. 2026).

GIUL, LLC v. SHENGHUO MEDICAL, LLC, & Others. (GIUL, LLC v. SHENGHUO MEDICAL, LLC, & Others.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Patry v. Liberty Mobilehome Sales, Inc.
475 N.E.2d 392 (Massachusetts Supreme Judicial Court, 1985)
Demoulas v. Demoulas Super Markets, Inc.
677 N.E.2d 159 (Massachusetts Supreme Judicial Court, 1997)
Marram v. Kobrick Offshore Fund, Ltd.
442 Mass. 43 (Massachusetts Supreme Judicial Court, 2004)
Chace v. Curran
881 N.E.2d 792 (Massachusetts Appeals Court, 2008)
Helwig v. Vencor, Inc.
251 F.3d 540 (Sixth Circuit, 2001)